



**THOMSON MEDICAL GROUP LIMITED**  
(Incorporated in the Republic of Singapore)  
(Company Registration No. 199908381D)

---

**S\$140,000,000 5.25% NOTES DUE 2027 TO BE ISSUED PURSUANT TO THE S\$1,000,000,000  
MULTICURRENCY DEBT ISSUANCE PROGRAMME OF THOMSON MEDICAL GROUP LIMITED**

---

The Board of Directors of Thomson Medical Group Limited (the "**Issuer**") wishes to announce that it has launched and priced S\$140,000,000 in aggregate principal amount of 5.25% notes due 2027 (the "**Series 004 Notes**"). The Series 004 Notes will be issued by the Issuer pursuant to the S\$1,000,000,000 Multicurrency Debt Issuance Programme established by the Issuer on 28 June 2019 and updated on 21 April 2023 (the "**Programme**"). DBS Bank Ltd. has been appointed as the sole global coordinator and DBS Bank Ltd., Maybank Securities Pte. Ltd., Oversea-Chinese Banking Corporation Limited, UBS AG Singapore Branch and United Overseas Bank Limited have been appointed as the joint lead managers and joint bookrunners in relation to the Series 004 Notes.

The principal terms of the Series 004 Notes are as follows:

<b>Issue Size:</b>	<b>S\$140,000,000</b>
<b>Issue Price:</b>	<b>100.00% of the principal amount of the Series 004 Notes</b>
<b>Denomination:</b>	<b>S\$250,000</b>
<b>Issuer's Redemption Option for Taxation Reasons:</b>	<b>At par, in accordance with the Programme</b>
<b>Issuer's Redemption Option in the case of Minimum Outstanding Amount:</b>	<b>At par, in accordance with the Programme</b>
<b>Noteholders' Redemption Option upon cessation or suspension of trading of shares:</b>	<b>At par, in accordance with the Programme</b>
<b>Interest:</b>	<b>5.25% per annum payable semi-annually in arrear</b>
<b>Maturity Date:</b>	<b>3 years from the date of issue</b>
<b>Security:</b>	<b>None</b>

The Series 004 Notes are expected to be issued on 13 May 2024 (subject to satisfaction of customary closing conditions) and listed on the Singapore Exchange Securities Trading Limited ("**SGX-ST**") on the market day after such issue.

The Series 004 Notes will constitute direct, unconditional and unsubordinated obligations of the Issuer and shall at all times rank *pari passu*, without any preference or priority among themselves, and at least *pari passu* with all other present and future unsecured obligations (other than subordinated obligations and priorities created by law) of the Issuer.

The Series 004 Notes are offered by the Issuer in Singapore pursuant to the exemptions invoked under Sections 274 and/or 275 of the Securities and Futures Act 2001 of Singapore.

The net proceeds arising from the issue of the Series 004 Notes under the Programme (after deducting issue expenses) will be used for refinancing of existing borrowings (including partial repayment of the acquisition loan for the Group's acquisition of Far East Medical Vietnam Limited) and general working capital of the Group.

Application will be made to the SGX-ST for the listing and quotation of the Series 004 Notes on the SGX-ST. Such permission will be granted when the Series 004 Notes have been admitted to the Official List of the SGX-ST. The SGX-ST assumes no responsibility for the correctness of any of the statements made, opinions expressed or reports contained herein. Approval in-principle from, admission to the Official List of, and the listing and quotation of the Series 004 Notes on, the SGX-ST are not to be taken as an indication of the merits of the Issuer, its subsidiaries, its associated companies (if any), the Programme or the Series 004 Notes.

**By Order of the Board**

**Wilson Sam**

Executive Director and Group Chief Financial Officer

6 May 2024